Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles.

ABSTRACT:

Background

Infections with influenza A virus (IAV) cause high morbidity and mortality in humans. Additional to vaccination, antiviral drugs are a treatment option. Besides FDA-approved drugs such as oseltamivir or zanamivir, virus-derived defective interfering (DI) particles (DIPs) are considered promising new agents. IAV DIPs typically contain a large internal deletion in one of their eight genomic viral RNA (vRNA) segments. Consequently, DIPs miss the genetic information necessary for replication and can usually only propagate by co-infection with infectious standard virus (STV), compensating for their defect. In such a co-infection scenario, DIPs interfere with and suppress STV replication, which constitutes their antiviral potential.

Results

In the present study, we gene

SUBMITTER: Hein MD 

PROVIDER: S-EPMC8091782 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature